Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Debt Repayments (2022 - 2024)

Ani Pharmaceuticals (ANIP) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $291.0 million as the latest value for Q3 2024.

  • Quarterly Long-Term Debt Repayments rose 19500.0% to $291.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $295.5 million through Sep 2024, up 39300.0% year-over-year, with the annual reading at $3.0 million for FY2023, 0.0% changed from the prior year.
  • Long-Term Debt Repayments hit $291.0 million in Q3 2024 for Ani Pharmaceuticals, up from $750000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $291.0 million in Q3 2024 to a low of -$1.5 million in Q3 2023.
  • Historically, Long-Term Debt Repayments has averaged $27.1 million across 3 years, with a median of $750000.0 in 2022.
  • Biggest five-year swings in Long-Term Debt Repayments: plummeted 300.0% in 2023 and later surged 19500.0% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $750000.0 in 2022, then skyrocketed by 300.0% to $3.0 million in 2023, then skyrocketed by 9600.0% to $291.0 million in 2024.
  • Business Quant data shows Long-Term Debt Repayments for ANIP at $291.0 million in Q3 2024, $750000.0 in Q2 2024, and $750000.0 in Q1 2024.